A Less Intensive Combination of Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer Patients who Have Aged 60 Years or More and Has a Poor Performance Status
The Korean Journal of Internal Medicine
;
: 109-113, 2004.
Article
Dans Anglais
| WPRIM
| ID: wpr-122275
ABSTRACT
BACKGROUND:
The aim of this study was to evaluate the response, survival, and toxicities of a less intensive combination of paclitaxel and carboplatin, which is used in advanced non-small cell lung cancer (NSCLC) patients older than 60 years of age including those with a poor performance status.METHODS:
Thirty patients received 135 mg/m2 of paclitaxel on day 1, and carboplatin was administered to the patients on day 1 every 4 weeks over an area under the concentration-time curve of 6.RESULTS:
The response rate was 40%, the median overall survival was 9.1 months (95% CI, 4.2 to 14 months), and the 1 year survival rate was 31%. The median progression-free survival was 7.7 months (95% CI, 3.1 to 12.2 months). In addition, the toxicities were generally mild and reversible.CONCLUSION:
This study demonstrates that a less intensive combination of paclitaxel/carboplatin is active and well tolerated in advanced NSCLC patients who are older than 60 years including those with a poor PS 3~4.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Calendrier d'administration des médicaments
/
Protocoles de polychimiothérapie antinéoplasique
/
Analyse de survie
/
Études de suivi
/
Carboplatine
/
Résultat thérapeutique
/
Paclitaxel
/
Carcinome pulmonaire non à petites cellules
/
Profil d'impact de la maladie
/
Relation dose-effet des médicaments
Type d'étude:
Étude observationnelle
/
Étude pronostique
Limites du sujet:
Adulte très âgé
/
Aged80
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
The Korean Journal of Internal Medicine
Année:
2004
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS